Literature DB >> 20148892

Binding of GTPgamma[35S] is regulated by GDP and receptor activation. Studies with the nociceptin/orphanin FQ receptor.

John McDonald1, David G Lambert.   

Abstract

BACKGROUND AND
PURPOSE: We have examined the effects of ligand efficacy and receptor density on the binding of guanosine 5'-[gamma-thio]triphosphate (GTPgammaS) and GDP to the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP)-coupled G-proteins. EXPERIMENTAL APPROACH: In GTPgamma[(35)S] binding experiments, using stable (CHO(hNOP)) and inducible (CHO(INDhNOP)) recombinant human and rat NOP we have measured: (i) ligand-specific GDP requirements; (ii) the effects of receptor density on guanine nucleotide affinity/capacity; and (iii) the effect of ligand efficacy on GTPgammaS association kinetics. KEY
RESULTS: GTPgammaS competition curves were shallow and modelled by high- and low-affinity components that were relatively consistent between cell types and tissue preparations. In the presence of 1 microM N/OFQ a high-affinity GDP binding site was also present, but the fraction of total binding was reduced. In an efficacy-dependent manner, the partial agonists [F/G]N/OFQ(1-13)NH(2) ([Phe(1)psi(CH(2)-NH)Gly(2)]-nociceptin(1-13)NH(2)) and naloxone benzoylhydrazone both reduced the fraction of high-affinity sites for GDP (relative to basal). While the pIC(50) for high-affinity GDP binding site did not decrease in the presence of 1 microM N/OFQ, N/OFQ produced a significant reduction in pIC(50) for the low-affinity site. Agonist-mediated decrease in affinity for GDP binding was efficacy-dependent. GDP displayed three affinities: high, conserved in the presence and absence of ligand; intermediate, present as a low fraction under basal conditions; low (efficacy-dependent), present during receptor activation representing the majority of binding. CONCLUSIONS AND IMPLICATIONS: The affinity of GTPgamma[(35)S] was regulated by GDP and receptor activation caused increased binding of GTPgamma[(35)S] through a reduction in GDP affinity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20148892      PMCID: PMC2848932          DOI: 10.1111/j.1476-5381.2009.00621.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  The nociceptin/orphanin FQ receptor ligand acetyl-RYYRIK-amide exhibits antagonistic and agonistic properties.

Authors:  H Berger; R Bigoni; E Albrecht; R M Richter; E Krause; M Bienert; G Calo'
Journal:  Peptides       Date:  2000-07       Impact factor: 3.750

Review 4.  Nociceptin/orphanin FQ receptor ligands.

Authors:  G Calo'; R Bigoni; A Rizzi; R Guerrini; S Salvadori; D Regoli
Journal:  Peptides       Date:  2000-07       Impact factor: 3.750

Review 5.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

6.  [Nphe(1)]NC(1-13)NH(2) selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain.

Authors:  H Berger; G Calo'; E Albrecht; R Guerrini; M Bienert
Journal:  J Pharmacol Exp Ther       Date:  2000-08       Impact factor: 4.030

7.  Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity.

Authors:  Y Cordeaux; S J Briddon; A E Megson; J McDonnell; J M Dickenson; S J Hill
Journal:  Mol Pharmacol       Date:  2000-11       Impact factor: 4.436

Review 8.  Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP.

Authors:  Nurulain Zaveri; Faming Jiang; Cris Olsen; Willma Polgar; Lawrence Toll
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

9.  The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential.

Authors:  David G Lambert
Journal:  Nat Rev Drug Discov       Date:  2008-08       Impact factor: 84.694

10.  Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors.

Authors:  R Bigoni; G Caò; A Rizzi; H Okawa; D Regoli; D Smart; D G Lambert
Journal:  Can J Physiol Pharmacol       Date:  2002-05       Impact factor: 2.273

View more
  3 in total

Review 1.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

2.  Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.

Authors:  James J Lu; Willma E Polgar; Anika Mann; Pooja Dasgupta; Stefan Schulz; Nurulain T Zaveri
Journal:  Mol Pharmacol       Date:  2021-05-06       Impact factor: 4.054

3.  Pharmacological Characterization of µ-Opioid Receptor Agonists with Biased G Protein or β-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation.

Authors:  Justyna Piekielna-Ciesielska; Roberto Artali; Ammar A H Azzam; David G Lambert; Alicja Kluczyk; Luca Gentilucci; Anna Janecka
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.